Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSun Yat-sen University
About this trial
This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.
Eligibility criteria
Qualifiers
were aged 18-75 years;
had recurrent HCC (RHCC) diagnosed by imaging studies, the first or the second RHCC;
RHCC met the Milan criteria, namely single RHCC lesion less than 5 cm in diameter or no more than 3 tumors (each ≤3 cm in diameter);
the early RHCC (recurrent time <1 year)
Disqualifiers
were under 18 years or over 75 years of age;
primary HCC;
recurrent HCC beyond Milan criteria;
RHCC with metastasis or macrovascular tumor thrombus
Trial design
Treatments tested in this trial
- Thermal ablation
- Donafenib
Treatment groups
108 Participants
are divided into 2 treatment groupsLocations
1Chinese PLA General hospital100853, BeijingNone Selected, China
Sponsors and collaborators
Sun Yat-sen University
Lead sponsor
Chinese PLA General Hospital
Collaborator
Source ClinicalTrials.gov